MediWound Ltd. (MDWD)
| Market Cap | 157.63M -20.5% |
| Revenue (ttm) | 11.86M -40.3% |
| Net Income | -20.18M |
| EPS | -2.25 |
| Shares Out | 12.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 93,059 |
| Open | 11.99 |
| Previous Close | 11.91 |
| Day's Range | 11.87 - 12.23 |
| 52-Week Range | 11.87 - 20.03 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 30.67 (+151.19%) |
| Est. Earnings | Nov 19, 2026 |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other ... [Read more]
Financial Performance
In 2025, MediWound's revenue was $16.96 million, a decrease of -16.14% compared to the previous year's $20.22 million. Losses were -$23.88 million, -20.99% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MDWD stock is "Strong Buy." The 12-month stock price target is $30.67, which is an increase of 151.19% from the latest price.
News
MediWound awarded additional $3.3M from DOW to advance NexoBrid
MediWound (MDWD) announced that the U.S. Department of War, DOW, has awarded the Company an additional $3.3M in non-dilutive funding to advance the development of a room-temperature-stable formulation...
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid ®
MediWound price target raised to $27 from $22 at Alliance Global
Alliance Global raised the firm’s price target on MediWound (MDWD) to $27 from $22 and keeps a Buy rating on the shares after the company announced that the DSMB did…
MediWound says DSMB recommends Phase 3 VALUE study continue without modification
On September 14, MediWound (MDWD) announced that the independent Data and Safety Monitoring Board completed its pre-specified periodic safety review of the ongoing Phase III VALUE study evaluating the...
MediWound Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Key growth drivers include the phase III VALUE trial for EscharEx, ongoing expansion of manufacturing capacity, and steady revenue from NexoBrid. Competitive positioning is strong, with faster debridement than legacy products and additional indications planned.
Independent DSMB Recommends MediWound's EscharEx® Phase III VALUE Study Continue Without Modification
Independent DSMB Recommends MediWound's EscharEx ® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment ...
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
MediWound to Present at the H.C. Wainwright 28 th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd.
MediWound reports Q2 EPS ($1.36), consensus (77c)
Reports Q2 revenue $4.57M, consensus $2.59M. “In the second quarter, we continued to make meaningful progress with our two key programs,” said Ofer Gonen, Chief Executive Officer of MediWound (MDWD).
MediWound backs FY26 revenue view $24M-$26M, consensus $24.13M
The company said, “The Company reaffirmed its full-year 2026 revenue guidance of $24-26 million, supported by expected second-half contributions from the MSA and other government-funded programs.”
MediWound price target lowered to $30 from $32 at Oppenheimer
Oppenheimer analyst Jeff Jones lowered the firm’s price target on MediWound (MDWD) to $30 from $32 and keeps an Outperform rating on the shares following quarterly results. Management reaffirmed its…
MediWound Earnings Call Transcript: Q2 2026
Q2 2026 saw progress in EscharEx's VALUE phase III trial and record NexoBrid U.S. sales, despite lower revenue due to BARDA timing. Full-year revenue guidance of $24–$26 million was reaffirmed, with growth expected in H2 from government contracts and new development programs.
MediWound Earnings release: Q2 2026
MediWound released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
MediWound Slides: Corporate presentation
MediWound has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract fo...
MediWound to Report Second Quarter 2026 Financial Results
MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd.
MediWound price target lowered to $22 from $25 at Alliance Global
Alliance Global lowered the firm’s price target on MediWound (MDWD) to $22 from $25 and keeps a Buy rating on the shares. The company’s Q1 results saw lower revenue and…
MediWound price target lowered to $32 from $33 at Oppenheimer
Oppenheimer lowered the firm’s price target on MediWound (MDWD) to $32 from $33 and keeps an Outperform rating on the shares after the company reported Q1 results and provided a…
MediWound Earnings Call Transcript: Q1 2026
Q1 2026 saw lower revenue due to BARDA timing and shipment delays, but gross margin improved. EscharEx and NexoBrid programs advanced, with a new $197M BARDA contract and reaffirmed 2026 revenue guidance of $24–26M, expecting a strong second half.
MediWound Earnings release: Q1 2026
MediWound released its Q1 2026 earnings on May 27, 2026, summarizing the period's financial results.
MediWound reports Q1 EPS (23c), consensus (66c)
Reports Q1 revenue $1.48M, consensus $3.37M. “During the first quarter, we continued to advance both our strategic and operational priorities,” said Ofer Gonen, CEO of MediWound (MDWD). “Enrollment co...
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue ...
MediWound Slides: Corporate presentation
MediWound has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
MediWound to Report First Quarter 2026 Financial Results
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd.
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive bi...
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support o...